H.B. Fuller, AMS, and the Capital Allocation Test Facing the Board

H.B. Fuller’s pursuit of Advanced Medical Solutions Group, or AMS, is not just an acquisition story. It is a corporate governance story about board oversight, leverage, and capital allocation discipline. Reuters reported that H.B. Fuller submitted an all-cash proposal on April 30, 2026, and had until June 18, 2026, under U.K. takeover rules to make a firm offer or walk away. Ancora says the move conflicts with a deleveraging-first posture. H.B. Fuller says disciplined M&A and balance-sheet improvement can coexist. [advfn.com], [gizmodo.com], [startribune.com], [cointelegraph.com]

In Detail

• What is happening? H.B. Fuller is pursuing a possible acquisition of Advanced Medical Solutions Group, a U.K.-based medical supplier, and Reuters reported the company had until June 18, 2026 to make a firm offer or walk away under U.K. takeover rules. [advfn.com], [gizmodo.com]

• Why does it matter? Ancora says the AMS pursuit contradicts a deleveraging-first framework and could raise leverage above 4.0x net debt / pro forma adjusted EBITDA. [startribune.com], [wsj.com]

• What is H.B. Fuller’s defense? The company says it has completed 13 acquisitions since the beginning of 2023 and reduced net debt to adjusted EBITDA to 3.1x from 3.5x a year earlier. [cointelegraph.com], [article.wn.com]

• What is the governance question? Whether the board can show that a potentially leverage-increasing cross-border deal is consistent with the capital-allocation discipline shareholders were led to expect. [startribune.com], [cointelegraph.com]

What is the real H.B. Fuller governance story?

In private equity, one of the first disciplines you learn is that a good company and a good use of capital are not the same thing. An attractive asset does not automatically make an acquisition disciplined. Timing matters. Leverage matters. Sequence matters. Above all, board credibility matters.

That is why the H.B. Fuller-AMS situation deserves attention. Reuters reported that Advanced Medical Solutions received an unsolicited takeover proposal from H.B. Fuller and that H.B. Fuller submitted an all-cash proposal on April 30, 2026. Reuters also reported that H.B. Fuller was engaged in due diligence and had until June 18, 2026 under U.K. takeover rules to announce a firm intention to make an offer or walk away. [advfn.com], [gizmodo.com]

The strategic rationale is easy enough to see. Reuters reported that AMS develops wound-care dressing technologies and that a transaction would strengthen H.B. Fuller’s push into high-margin medical adhesives and wound-care products while diversifying revenue. [advfn.com], [gizmodo.com]

But boards are not measured by whether they can identify attractive narratives. They are measured by whether they can allocate capital in a way that is consistent, disciplined, and credible.

Why is Ancora opposing the AMS deal?

Ancora’s objection is not subtle. In a public letter released on May 26, 2026, Ancora said it owns more than 2% of H.B. Fuller’s outstanding common stock and urged the board to abandon the AMS pursuit and conduct a full review of strategic alternatives, including evaluating a sale of all or parts of the business. [startribune.com], [wsj.com]

Ancora argued that management’s pursuit of AMS contradicted what it described as a March 26 public commitment to avoid near-term deals in favor of necessary deleveraging. Ancora also said the proposed acquisition could raise leverage to above 4.0x net debt / pro forma adjusted EBITDA. [startribune.com], [wsj.com]

That is what gives the dispute real governance gravity. This is not simply an argument about whether AMS is strategically attractive or whether the price is right. It is an argument about whether the board is acting consistently with the capital-allocation framework shareholders believed management had established. Ancora’s letter says shareholders felt “completely misled” by the disclosure that H.B. Fuller had made an offer for AMS after earlier signals that deleveraging, not major near-term M&A, was the priority. [startribune.com]

From a governance perspective, that is the issue that matters most: when does strategic flexibility stop looking thoughtful and start looking inconsistent?

How has H.B. Fuller responded?

H.B. Fuller has responded with a serious defense, not a rhetorical one. In its May 26, 2026 statement, the company said its board and management value shareholder feedback and described its M&A strategy as “thoughtful and disciplined.” The company said it has completed 13 acquisitions since the beginning of 2023, and that those transactions have contributed to adjusted EBITDA growth and margin expansion through synergy capture. [cointelegraph.com], [article.wn.com]

H.B. Fuller also said it has been “methodically deleveraging” its balance sheet, reducing net debt to adjusted EBITDA to 3.1x at the end of the first quarter from 3.5x in the same period a year earlier. It added that disclosure regarding AMS was required by the U.K. Takeover Code and that there is no certainty a binding offer will be made. [cointelegraph.com], [article.wn.com]

That response matters because it sharpens the real dispute. H.B. Fuller is not saying leverage no longer matters. It is saying that disciplined acquisitions and deleveraging can coexist. That is the company’s core argument, and it is the one the board will have to substantiate if it proceeds. [cointelegraph.com]

Why this is a capital allocation story first

Experienced investors tend to look at situations like this through a simple sequence of questions:

1. What is the asset? Reuters reported that AMS would deepen H.B. Fuller’s position in medical adhesives and wound-care products. [advfn.com], [gizmodo.com]

2. What is the balance-sheet impact? Ancora says leverage could move above 4.0x net debt / pro forma adjusted EBITDA. H.B. Fuller says net debt to adjusted EBITDA stood at 3.1x at the end of the first quarter, down from 3.5x a year earlier. [startribune.com], [wsj.com], [cointelegraph.com], [article.wn.com]

3. What did management previously signal? Ancora says H.B. Fuller had conveyed a near-term emphasis on deleveraging rather than material M&A. [startribune.com], [wsj.com]

4. Can the board explain why this deal, now? That is the live governance question raised by the public disagreement between Ancora and H.B. Fuller. [startribune.com], [cointelegraph.com]

This is the point boards sometimes miss. Markets are capable of understanding a controversial acquisition. What they are less forgiving of is a board that appears to change the hierarchy of capital-allocation priorities without acknowledging the change or carrying the burden of proof.

In my view, that is the heart of the H.B. Fuller situation. The issue is not only whether AMS is a desirable asset. The issue is whether the board can demonstrate that pursuing AMS is consistent with discipline rather than a suspension of it. That sentence is my interpretation, but it is grounded in the public clash between Ancora’s deleveraging critique and H.B. Fuller’s defense of its acquisition framework. [startribune.com], [cointelegraph.com]

What sophisticated investors are really watching

The most sophisticated investors are unlikely to ask only whether AMS is attractive. They are more likely to ask three harder questions.

1. Is the board preserving capital allocation credibility?

Ancora says the AMS pursuit contradicts a deleveraging-first commitment. H.B. Fuller says its M&A strategy remains disciplined and compatible with balance-sheet improvement. [startribune.com], [cointelegraph.com]

2. Is the board respecting sequence?

If management has been emphasizing deleveraging, investors will expect the board to explain why a potentially larger, cross-border acquisition belongs in that sequence now rather than later. This is an interpretive conclusion drawn from the public dispute, not a quoted company statement. [startribune.com], [cointelegraph.com]

3. Does the board still look like it governs from a framework?

H.B. Fuller has pointed to 13 acquisitions since the beginning of 2023 and a reduction in net debt to adjusted EBITDA to 3.1x from 3.5x a year earlier. Ancora has pointed to the possibility of leverage moving above 4.0x if AMS is acquired. Those facts frame the central test of board judgment. [cointelegraph.com], [article.wn.com], [startribune.com], [wsj.com]

My view: this is a board credibility test

My view is that H.B. Fuller’s board is being tested less on appetite for M&A than on credibility in capital allocation. That does not mean Ancora is automatically right. It also does not mean AMS is automatically the wrong asset. It means the board cannot rely on the generic logic that the target is attractive or strategically adjacent. It has to explain, with precision, why this transaction fits the company’s balance-sheet posture, leverage tolerance, and stated priorities.

Boards do not usually lose credibility in a single moment. More often, they lose it incrementally, when investors start to suspect that strategy is being rewritten opportunistically rather than applied consistently. That final sentence is my opinion, but the reason it is relevant here is the public collision between Ancora’s claim of inconsistency and H.B. Fuller’s claim of discipline. [startribune.com], [cointelegraph.com]

If H.B. Fuller proceeds, the board will need to show that the deal is a disciplined expression of strategy. If it walks away, investors may conclude that the board chose to preserve credibility rather than stretch the framework. Reuters reported that the company had until June 18, 2026 under U.K. takeover rules to make that decision. [advfn.com], [gizmodo.com]

That is why this is a governance story. Not because every activist is right. Not because every acquisition is suspect. But because moments like this reveal whether a board is truly governing or merely rationalizing.

What investors should watch next

Whether H.B. Fuller makes a firm offer for AMS by June 18, 2026. Reuters reported that this is the relevant deadline under U.K. takeover rules. [advfn.com], [gizmodo.com]

Whether the board explains how any AMS transaction aligns with deleveraging and capital allocation discipline. Ancora says the pursuit conflicts with a deleveraging-first posture, while H.B. Fuller says disciplined M&A and deleveraging can coexist. [startribune.com], [cointelegraph.com]

Whether investors accept management’s framework. That is my interpretive takeaway: in public markets, trust in the decision-making framework often matters almost as much as the decision itself.

FAQ: H.B. Fuller, AMS, and Ancora

What is H.B. Fuller trying to do?

Reuters reported that H.B. Fuller submitted an all-cash proposal for Advanced Medical Solutions on April 30, 2026, and had until June 18, 2026 under U.K. takeover rules to make a firm offer or walk away. [advfn.com], [gizmodo.com]

Why is Ancora opposing the deal?

Ancora said H.B. Fuller’s pursuit of AMS contradicts a deleveraging-first commitment, urged the board to review strategic alternatives, and said leverage could rise above 4.0x net debt / pro forma adjusted EBITDA. [startribune.com], [wsj.com]

How has H.B. Fuller responded?

H.B. Fuller said it has a disciplined M&A strategy, has completed 13 acquisitions since the beginning of 2023, and has reduced net debt to adjusted EBITDA to 3.1x from 3.5x a year earlier. It also said there is no certainty a binding offer for AMS will be made. [cointelegraph.com], [article.wn.com]

Why is this a corporate governance issue?

Because the dispute is about more than strategic fit. It is about board oversight, capital allocation, leverage discipline, and whether management’s actions are consistent with what shareholders were led to expect. [startribune.com], [cointelegraph.com]